NO933261L - Blanding til forsterkning av immunforsvaret - Google Patents

Blanding til forsterkning av immunforsvaret

Info

Publication number
NO933261L
NO933261L NO933261A NO933261A NO933261L NO 933261 L NO933261 L NO 933261L NO 933261 A NO933261 A NO 933261A NO 933261 A NO933261 A NO 933261A NO 933261 L NO933261 L NO 933261L
Authority
NO
Norway
Prior art keywords
antigen
immunogen
forms
strengthening
mixture
Prior art date
Application number
NO933261A
Other languages
English (en)
Other versions
NO313178B1 (no
NO933261D0 (no
Inventor
Robert S Becker
Karen Biscardi
Laura Ferguson
Lorne Franklin Erdile
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25479200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO933261(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of NO933261D0 publication Critical patent/NO933261D0/no
Publication of NO933261L publication Critical patent/NO933261L/no
Publication of NO313178B1 publication Critical patent/NO313178B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0225Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • A61K2039/55594Adjuvants of undefined constitution from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jib Cranes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Radar Systems Or Details Thereof (AREA)
NO19933261A 1992-09-14 1993-09-13 Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle NO313178B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94317392A 1992-09-14 1992-09-14

Publications (3)

Publication Number Publication Date
NO933261D0 NO933261D0 (no) 1993-09-13
NO933261L true NO933261L (no) 1994-03-15
NO313178B1 NO313178B1 (no) 2002-08-26

Family

ID=25479200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933261A NO313178B1 (no) 1992-09-14 1993-09-13 Sammensetning til fremskaffelse av en immunrespons mot et antigen hos et dyr, sett til anvendelse derav, samt anvendelse aven först opplöselig form av et antigen og en andre uopplöseligform av antigenet ved fremstilling av sammensetningen elle

Country Status (15)

Country Link
US (4) US5662909A (no)
EP (1) EP0588578B2 (no)
JP (1) JP2512689B2 (no)
AT (1) ATE187338T1 (no)
AU (1) AU677592B2 (no)
CA (1) CA2105629A1 (no)
DE (1) DE69327214T3 (no)
DK (1) DK0588578T4 (no)
ES (1) ES2141750T5 (no)
FI (1) FI110234B (no)
GR (1) GR3032543T3 (no)
IL (2) IL106968A (no)
NO (1) NO313178B1 (no)
PT (1) PT588578E (no)
ZA (1) ZA936629B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 改変hivenvポリペプチド
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20050106137A1 (en) * 2000-05-05 2005-05-19 Stephen Grimes Chimeric peptide immunogens
DE122011100043I1 (de) * 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
EP2280074A3 (en) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
EP1411770A4 (en) * 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US6814729B2 (en) 2002-06-27 2004-11-09 Technovision Gmbh Laser vision correction apparatus and control method
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4946676A (en) * 1986-08-27 1990-08-07 De Staat Der Nederlanden Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao

Also Published As

Publication number Publication date
FI934013L (fi) 1994-03-15
NO313178B1 (no) 2002-08-26
ES2141750T3 (es) 2000-04-01
GR3032543T3 (en) 2000-05-31
DK0588578T3 (da) 2000-03-27
JPH06192125A (ja) 1994-07-12
ZA936629B (en) 1994-03-30
EP0588578B1 (en) 1999-12-08
FI110234B (fi) 2002-12-31
US5853736A (en) 1998-12-29
DE69327214T2 (de) 2000-09-07
EP0588578B2 (en) 2005-04-13
US5662909A (en) 1997-09-02
JP2512689B2 (ja) 1996-07-03
EP0588578A1 (en) 1994-03-23
NO933261D0 (no) 1993-09-13
FI934013A0 (fi) 1993-09-14
ES2141750T5 (es) 2005-12-01
US6024963A (en) 2000-02-15
DK0588578T4 (da) 2005-07-25
ATE187338T1 (de) 1999-12-15
AU677592B2 (en) 1997-05-01
CA2105629A1 (en) 1994-03-15
PT588578E (pt) 2000-05-31
IL106968A (en) 1999-10-28
AU4622693A (en) 1994-03-24
US5837264A (en) 1998-11-17
DE69327214D1 (de) 2000-01-13
IL106968A0 (en) 1993-12-28
DE69327214T3 (de) 2005-12-01
IL130075A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
NO933261L (no) Blanding til forsterkning av immunforsvaret
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
NO982861D0 (no) Stabilisatorer for levende vaksiner
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
DK0914114T3 (da) Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
FI823021A7 (fi) Tuotteet, jotka osoittavat hepatitis B virus e antigeenin antigeenisuuden ja menetelmät näiden antigeenien vavalmistamiseksi.
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
FI972054A0 (fi) Immunogeenisiä koostumuksia
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
ES2056780T1 (es) Un procedimiento para el aislamiento de virus de hav.
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
FI943295A0 (fi) Piliostigma thonningii -uutteet, niiden käyttö ja Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit niitä sisältävät formuloinnit
Hayami et al. CELL MEDIATED IMMUNITY AGAINST AVIAN VIRUS-INDUCED TUMOR CELLS